vs
CareTrust REIT, Inc.（CTRE）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是CareTrust REIT, Inc.的1.5倍（$197.9M vs $134.9M），CareTrust REIT, Inc.净利率更高（82.5% vs 6.7%，领先75.8%），CareTrust REIT, Inc.同比增速更快（55.1% vs 13.6%），过去两年CareTrust REIT, Inc.的营收复合增速更高（46.2% vs 14.4%）
本公司是一家英国房地产投资企业，专注于医疗类不动产投资，持有规模庞大的养老护理院资产组合。公司采用房地产投资信托（REIT）架构，在伦敦证券交易所上市，是富时250指数成分股。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
CTRE vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.5倍
$134.9M
营收增速更快
CTRE
高出41.5%
13.6%
净利率更高
CTRE
高出75.8%
6.7%
两年增速更快
CTRE
近两年复合增速
14.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $134.9M | $197.9M |
| 净利润 | $111.3M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | — | 9.0% |
| 净利率 | 82.5% | 6.7% |
| 营收同比 | 55.1% | 13.6% |
| 净利润同比 | 113.5% | 143.9% |
| 每股收益（稀释后） | $0.52 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTRERGEN
| Q4 25 | $134.9M | $197.9M | ||
| Q3 25 | $132.4M | $188.8M | ||
| Q2 25 | $112.5M | $182.4M | ||
| Q1 25 | $96.6M | $169.2M | ||
| Q4 24 | $86.9M | $174.1M | ||
| Q3 24 | $77.4M | $154.9M | ||
| Q2 24 | $68.9M | $154.1M | ||
| Q1 24 | $63.1M | $151.3M |
净利润CTRERGEN
| Q4 25 | $111.3M | $13.3M | ||
| Q3 25 | $74.9M | $14.9M | ||
| Q2 25 | $68.5M | $14.9M | ||
| Q1 25 | $65.8M | $5.8M | ||
| Q4 24 | $52.1M | $-30.3M | ||
| Q3 24 | $33.4M | $-654.0K | ||
| Q2 24 | $10.8M | $3.3M | ||
| Q1 24 | $28.7M | $2.1M |
毛利率CTRERGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率CTRERGEN
| Q4 25 | — | 9.0% | ||
| Q3 25 | 58.1% | 8.9% | ||
| Q2 25 | 61.3% | 7.6% | ||
| Q1 25 | — | 3.9% | ||
| Q4 24 | — | -17.7% | ||
| Q3 24 | 43.0% | -5.1% | ||
| Q2 24 | 15.1% | 1.0% | ||
| Q1 24 | — | 1.3% |
净利率CTRERGEN
| Q4 25 | 82.5% | 6.7% | ||
| Q3 25 | 56.6% | 7.9% | ||
| Q2 25 | 60.9% | 8.2% | ||
| Q1 25 | 68.1% | 3.4% | ||
| Q4 24 | 60.0% | -17.4% | ||
| Q3 24 | 43.2% | -0.4% | ||
| Q2 24 | 15.6% | 2.2% | ||
| Q1 24 | 45.6% | 1.4% |
每股收益（稀释后）CTRERGEN
| Q4 25 | $0.52 | $0.24 | ||
| Q3 25 | $0.35 | $0.26 | ||
| Q2 25 | $0.35 | $0.26 | ||
| Q1 25 | $0.35 | $0.10 | ||
| Q4 24 | $0.30 | $-0.55 | ||
| Q3 24 | $0.21 | $-0.01 | ||
| Q2 24 | $0.07 | $0.06 | ||
| Q1 24 | $0.22 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.0M | $767.6M |
| 总债务越低越好 | $894.2M | $542.2M |
| 股东权益账面价值 | $4.0B | $2.1B |
| 总资产 | $5.1B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.22× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资CTRERGEN
| Q4 25 | $198.0M | $767.6M | ||
| Q3 25 | $712.5M | $748.7M | ||
| Q2 25 | $306.1M | $708.9M | ||
| Q1 25 | $26.5M | $697.2M | ||
| Q4 24 | $213.8M | $757.4M | ||
| Q3 24 | $377.1M | $784.0M | ||
| Q2 24 | $495.1M | $809.1M | ||
| Q1 24 | $451.2M | $780.6M |
总债务CTRERGEN
| Q4 25 | $894.2M | $542.2M | ||
| Q3 25 | $893.8M | $537.9M | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $822.1M | — | ||
| Q4 24 | $396.9M | $525.6M | ||
| Q3 24 | $396.7M | — | ||
| Q2 24 | $671.1M | — | ||
| Q1 24 | $595.9M | — |
股东权益CTRERGEN
| Q4 25 | $4.0B | $2.1B | ||
| Q3 25 | $4.0B | $2.1B | ||
| Q2 25 | $3.3B | $2.1B | ||
| Q1 25 | $2.9B | $2.0B | ||
| Q4 24 | $2.9B | $2.0B | ||
| Q3 24 | $2.4B | $2.0B | ||
| Q2 24 | $1.9B | $2.0B | ||
| Q1 24 | $1.7B | $2.0B |
总资产CTRERGEN
| Q4 25 | $5.1B | $2.9B | ||
| Q3 25 | $5.1B | $2.9B | ||
| Q2 25 | $4.7B | $2.9B | ||
| Q1 25 | $3.9B | $2.9B | ||
| Q4 24 | $3.4B | $2.8B | ||
| Q3 24 | $2.9B | $2.8B | ||
| Q2 24 | $2.7B | $2.9B | ||
| Q1 24 | $2.3B | $2.8B |
负债/权益比CTRERGEN
| Q4 25 | 0.22× | 0.26× | ||
| Q3 25 | 0.22× | 0.26× | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.28× | — | ||
| Q4 24 | 0.14× | 0.27× | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $394.0M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | — | $17.6M |
| 自由现金流率自由现金流/营收 | — | 8.9% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | 3.54× | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流CTRERGEN
| Q4 25 | $394.0M | $25.7M | ||
| Q3 25 | $100.9M | $48.1M | ||
| Q2 25 | $100.8M | $28.6M | ||
| Q1 25 | $71.4M | $15.0M | ||
| Q4 24 | $244.3M | $39.2M | ||
| Q3 24 | $67.2M | $49.3M | ||
| Q2 24 | $53.0M | $42.2M | ||
| Q1 24 | $48.8M | $44.7M |
自由现金流CTRERGEN
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $43.4M | ||
| Q2 25 | — | $21.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $33.6M | ||
| Q3 24 | — | $42.3M | ||
| Q2 24 | — | $37.4M | ||
| Q1 24 | — | $36.4M |
自由现金流率CTRERGEN
| Q4 25 | — | 8.9% | ||
| Q3 25 | — | 23.0% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 27.3% | ||
| Q2 24 | — | 24.3% | ||
| Q1 24 | — | 24.0% |
资本支出强度CTRERGEN
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 3.1% | ||
| Q1 24 | — | 5.5% |
现金转化率CTRERGEN
| Q4 25 | 3.54× | 1.93× | ||
| Q3 25 | 1.35× | 3.23× | ||
| Q2 25 | 1.47× | 1.92× | ||
| Q1 25 | 1.08× | 2.57× | ||
| Q4 24 | 4.68× | — | ||
| Q3 24 | 2.01× | — | ||
| Q2 24 | 4.92× | 12.70× | ||
| Q1 24 | 1.70× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
